Glenmark Pharma ties up with Menarini for commercializing Ryaltris Nasal Spray
Glenmark Pharma ties up with Menarini for commercializing Ryaltris Nasal Spray Mumbai, Dec 23 (UNI) Pharma major, Glenmark Pharma on Wednesday said that its Swiss subsidiary, Glenmark Specialty S.A., has entered into an exclusive licensing agreement with Menarini Group (Menarini) for commercializing its innovative nasal spray Ryaltris across 33 countries in Europe, including the Balkan region. Ryaltris [olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg)], developed by Glenmark, is a novel fixed-dose combination nasal spray of an anti-histamine and a steroid, indicated for tr...